Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism - Tập 8 Số 4 - Trang 419-428 - 2006
Robert E. Ratner1, David Maggs2, Loretta L. Nielsen2, Anthony H. Stonehouse2, Terri Poon2, B. Zhang2, Thomas A. Bicsak2, Robert G. Brodows3, D. D. Kim2
1MedStar Research Institute, Hyattsville, MD, USA
2Amylin Pharmaceuticals, Inc, San Diego, CA, USA
3Eli Lilly and Company, Indianapolis, IN, USA

Tóm tắt

Aim:  The ability of the incretin mimetic exenatide to improve glycaemic control and reduce body weight was assessed over 82 weeks in patients with type 2 diabetes failing to achieve glycaemic control with maximally effective doses of metformin.Methods:  In this interim 82‐week analysis, 150 (total cohort) of an eligible population of 183 patients opted to continue exenatide treatment in an uncontrolled open‐label extension of a 30‐week double‐blind, placebo‐controlled trial. Of these, 92 patients (completer cohort) achieved 82 weeks of exenatide therapy. Patients continued metformin throughout the study.Results:  At the end of the placebo‐controlled trial, exenatide resulted in an haemoglobin A1c (HbA1c) reduction from baseline of −1.0 ± 0.1% (mean ± SE) (exenatide treatment arms), with durable HbA1c reductions after 82 weeks of −1.3 ± 0.1%. The percent of patients who achieved HbA1c≤7% at weeks 30 and 82 was 46 and 59% respectively. After 30 weeks, exenatide caused a reduction in weight from baseline of −3.0 ± 0.6 kg, with a progressive reduction in weight of −5.3 ± 0.8 kg after 82 weeks. In addition, exenatide treatment produced clinically significant improvements in cardiovascular risk factors after 82 weeks. The most frequent adverse event after 30 and 82 weeks of exenatide was nausea, which was generally of mild‐or‐moderate intensity. It decreased in incidence after initiation in the controlled trial and the uncontrolled open‐label extension. Hypoglycaemia was rare, with no severe events.Conclusion:  Exenatide was generally well tolerated, producing a durable reduction in HbA1c and a progressive reduction in weight over 82 weeks in patients with type 2 diabetes failing to achieve glycaemic control with metformin.

Từ khóa


Tài liệu tham khảo

10.1172/JCI7231

10.2337/diab.44.11.1249

10.1016/S0140-6736(98)07019-6

10.2337/diacare.27.1.17

10.2337/diacare.22.3.403

10.1001/jama.287.3.360

10.7326/0003-4819-131-4-199908170-00008

10.1016/S0140-6736(98)07037-8

10.1056/NEJM199508313330902

10.7326/0003-4819-137-1-200207020-00009

10.1056/NEJMcp021106

10.1210/jc.2002-021545

10.2337/diacare.26.8.2370

Nielsen LL, 2003, Pharmacology of exenatide (synthetic exendin‐4) for the treatment of type 2 diabetes, Curr Opin Investig Drugs, 4, 401

10.1053/meta.2001.22519

10.1152/ajpendo.2001.281.1.E155

10.1016/j.regpep.2003.10.028

10.1210/jcem.87.3.8337

10.1002/dmrr.328

10.1152/ajpendo.00545.2003

10.1016/S0140-6736(02)07952-7

10.1210/endo.141.6.7490

10.1210/en.2004-1349

10.1210/jc.2005-1093

10.2337/diacare.28.5.1092

World Medical Association declaration of Helsinski., 1997, Recommendations guiding medical physicians in biomedical research involving human subjects, JAMA, 277, 925, 10.1001/jama.1997.03540350075038

10.2337/diacare.27.11.2628

10.2337/diacare.28.5.1083

10.1001/archinte.164.5.486

10.1089/152091599317143

10.2337/diacare.24.6.983

10.1016/S0168-8227(98)00062-X

10.2165/00024677-200302010-00004

10.2337/diacare.17.10.1100

10.1016/S0168-8227(99)00002-9

Campbell IW, 1994, One year comparative trial of metformin and glipizide in type 2 diabetes mellitus, Diabetes Metab, 20, 394

10.1016/j.ecl.2004.11.004

10.1111/j.1742-1241.2004.00318.x

10.1001/jama.283.13.1695

10.1002/dmrr.478

Maggs D, 2005, Exenatide‐induced reductions in A1C and body weight in long‐term trials are not explained by gastrointestinal side effects, Diabetes, 54, 485

Thông tin
Thông tin xuất bản

Diabetes, Obesity and Metabolism

Tập 8 Số 4

419-428

Thông tin tác giả